acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amazing what a few traders with 5,000,000 shares and a $1,000,000 can do the share price if the attack is coordinated.
I suspect Lincoln Park Capital wanted a lower share price and had the perfect situation to manipulate the stock lower to get it. A "quiet period" at the right time.
It happens with penny stocks.
p.s. Buy for the run-up. That's how they double their profits by making money in each direction.
All IMHO.
p.s. It's probably closer to $40,000,000.
$2,400,000 In Trading Volume Dropped the Market Cap $35,000,000
Over the last eight trading sessions.
Amazing what low trading volume can do to a penny stock when there is no news.
This is substantially oversold.
I added more shares today but I'm done buying.
Still can't imagine why there hasn't been a "peep" out of Gerald while the share price has been getting hammered.
I still think it's a gift at the current price but my available funds are being used for trading a few oil and gold stocks.
Let's hope that the silence has been justified due to a quiet period.
Alzheimer's diagnostics will soon be a "hot topic".
$AMBS is a gift at the current price.
If you're not buying at these levels you are missing one of the best opportunities in the market both short and long term.
Twitter: @AmarantusBio
LymPro - MANF - ESS - Eltoprazine - Each May Be Worth More than the Current Market Cap.
Load the truck at seven cents. It isn't going much lower.
Stay tuned for news.
I think Gerald is waiting until the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders being held March 18-22, 2015, in Nice, France to release news.
The company has a poster presentation on LymPro and the conference offers a "global stage" for significant news. Gerald is overdue to hit a "home run" at one of these conferences. Why not this one?
Interesting week ahead.
p.s. To anyone who is unhappy with the company's accomplishments to date I suggest you sell your shares and invest in the other penny stock that offers the same potential as $AMBS. By the way what was that other penny stock?
I've been adding shares as the share price has been dropping.
As I previously posted, all the options held by insiders are at an exercise price of eight cents or higher. Also any of the four products currently in the pipeline (many more than four with the various orphan indications for MANF) have the potential to be worth many times Amarantus' current market cap.
When thinking of selling a stock which I own at a higher price I ask myself if I didn't own the stock and had just heard about it would I be buying it here. If the answer is yes then I certainly wouldn't sell and in fact would be adding shares as I have been doing.
Amarantus is undervalued and is still unknown to the market at large.
I believe that by the end of the week we'll have a much better idea of Gerald's business plan for 2015.
Overdue for substantive news. I don't see it going lower than .065.
I bought 1,000,000 shares the last two days. Have buy order in place for another 500,000 at .0651.
I think it will end next week back above .09.
Just a hunch.
Obviously if you're that concerned I suggest that you wait until the share price is in the .25 - .30 range before you buy shares. By then the need to sell additional shares will have diminished.
Best of luck with your other investments.
$AMBS Offer So Much Upside for a Stock Trading Under A Dime
"We believe Amarantus will seek a commercial partner for eltoprazine after the Phase 2b data if successful. There are an estimated 16,000 neurologists in the U.S, about half of which specialize in movement disorders or treat Parkinson’s patients. This is clearly a specialty pharmaceutical promotion. We believe with strong Phase 2b data, Amarantus can partner eltoprazine for $30 to $50 million upfront and $300 to $400 million in total potential. We are using the May 2009 transaction between Acadia Pharma and Biovail for pimavanserin ($30 million upfront + $365 million total potential) as the key basis for what a deal might look like. In May 2009, pimavanserin was coming off positive Phase 2 data and had development potential in PDP, Alzheimer’s disease psychosis, and schizophrenia."
Eltoprazine is only one of the products in $AMBS' pipeline:
http://www.amarantus.com/pipeline
Consider $AMBS which is currently trading under a dime.
300-500% upside this year is possible.
$AMBS Should Be Trading In the .15+ Range
The company has four products in its pipeline (seven if you include the various orphan indications for MANF) each of which could justify a market cap three to five times the current one.
It's only a matter of time before a singular catalyst will double the share price.
Stay tuned for news.
Twitter: @AmarantusBio
Gerald's comments:
"I'd be buying all day long here."
"2015 will be a monumental year for the company."
The last thirty years has focused on the "War Against Cancer"
The next thirty years will focus on the "Attack on Alzheimer's".
If you consider the various companies that are positioned to benefit from the "purple" campaign $AMBS would have to be at the top of the list.
Twitter: @AmarantusBio
Evidently I have a better source of information than anyone here.
.50 in six months or sooner. :)
My thought on where it's headed:
Bear raid today to steal cheap shares.
Dime, quarter, dollar.
Sounds like a reasonable price movement over the next year.
Another day closer to "monumental news".
Currently own 3.895 million at .0278.
Easy triple by the end of February or sooner.
My view of the current opportunity with $AMBS:
When Gerald stated in his "off mic" comment that he'd be "buying all day long" at the current share price that was as close to insider information that I had available to me.
He stated in his recent blog that 2015 will be a monumental year for the company. Who would know better than Gerald? Just think of all the "under the radar" accomplishments that the management team has achieved over the last six months. I'm just waiting to see what will be the catalyst that doubles or triples the share price overnight.
As I posted before, "less than a penny to the downside versus dollars to the upside".
2015 will not only be a monumental year for the company but it will also be a very monumental year for the shareholders.
Stay tuned for news.
All IMHO.
It seems to me that a smart group of investment bankers could package the diagnostic pipeline with the potential of a $3,000,000,000 annual market in such a manner to raise a minimum of $150,000,000 from an I.P.O.
Anyone selling at the current price is giving away shares which I think will be in the .20-.25 range some time this year.
Stay tuned for news.
Twitter: @AmarantusBio .... 10,200 followers.
"McDermott's Recent GE Deal And More Details On This $2 Stock"
http://seekingalpha.com/article/2867606-mcdermotts-recent-ge-deal-and-more-details-on-this-2-stock
Good info.
I wouldn't be surprised to see the share price back above $3.00 by Friday as the traders continue to exit.
I think there's a better chance that the share price hits $3.00 before it hits $2.00 again.
Upside potential outweighs the downside risk at the current share price.
p.s. Go Patriots!!!
McDermott International (MDR),GE's partner in the oil industry, offers substantial upside.
http://seekingalpha.com/article/2867606-mcdermotts-recent-ge-deal-and-more-details-on-this-2-stock
MDR's share price could easily double over the next twelve months, or sooner with a buyout offer.
GE could be a potential suitor.
Two things you need to know:
1. "We have very recently been approached by a number of leading investment banks to evaluate strategic options for the diagnostics business unit, and are now evaluating the options in this area."
2. Gerald's comment: "I'd be buying all day long here."
Twitter: @AmarantusBio .... 10,200 followers
p.s. .15-.20 by April 1 or sooner.
Load the truck under three cents.
This will be at an all time high by the end of February.
Stay tuned for news!!!
Chirp!!! Chirp!!! Chirp!!!
$MDR - Option Alert: McDermott Jan 2016 $5.00 Call; 1000 Contract Trade at Ask @$0.40; Now $2.19
http://www.benzinga.com/markets/options/15/01/5187885/option-alert-mcdermott-jan-2016-5-00-call-1000-contract-trade-at-ask-0#ixzz3QB8Zz7cI
For what it's worth.
Just spoke with a friend of mine who says there's a number of items in the works with news in February. He said to buy all I can afford at the current price.
He owns over four million shares and he bought more shares today.
Does anyone know what the number of authorized shares is for NTEK?
Seems as though someone has an unlimited number of shares to keep dumping on the bid.
Just saying!!!
p.s. I had a buy order in at .02 but I just pulled it.
You have to admit that Gerald "spins a good tale".
I recall that Gerald stated last August that the company had filed a total of six applications for various sources of grant funding and would continue to file in the future. One has to wonder that with the talented management group on board and the extensive pipeline why the company hasn't received a single grant in over a year.
In any event let's hope that substantive news that will double or triple the share price is just around the corner.
Twitter: @AmarantusBio
p.s. I'm still expecting the share price to be above .15 by April 1. Just a hunch!!!
GLTY
Trading at less than "cash on hand" currently.
Prime takeover target. GE?
Substantial upside from here.
With all the potential known catalysts that are currently "in play" I think your price targets are reasonable.
I currently own 112,000 shares so my expectations may be higher than others who may own less shares.
Interesting weeks and months ahead.
Twitter: @AmarantusBio .... 10,200 followers.
Five office locations and 54 employees.
I'm adding here.
p.s. I'd like to buy more shares under three cents in the event someone wants to sell.
A penny to the downside versus dollars to the upside.
Place your bet.
Did Everyone Here What Gerald Told the Attendee Before the Start of the Presentation?
Before the start of the presentation an attendee was talking to Gerald and told Gerald that he "had a lot of money riding on him" . The attendee commented about the share price being where it is and Gerald made the comment that if he weren't who he is that he'd be buying all day long at eight cents.
Gerald also stated he was going from Florida to Boston.
Gerald also stated that the company was done with acquisitions for now. Also he stated that the company has so many products in development that any concerns about one product being delayed would have minimal impact.
Then Gerald asked someone if the actual presentation was ready to go and he started it. Don't know if the "prelude" will be cut out on the archived webcast. Check it out.
Hopefully Gerald's next Chairman's blog will present some definitive timelines for milestones/catalysts in 2015.
I thought you were a major supporter of Gerald's acumen in the biotech space?
I think Gerald's C.E.O./Chairman's blog on the "State of the Company" should be out soon.
Should be an interesting read.
Wanting to see what his anticipated milestones are for 2015 and when he expects they will occur.
Today's "tweet" from Jason Napadano:
Jason Napodano, CFA ?@JNapodano
Some of my better ideas right now: $CYNAF $CUR $NVIV $EPRS $ASPX $NBIX $LPCN $VCEL
Do you happen to notice what company didn't make the list?
Just saying!!!
Back on the AMBS Bus
After considerable thought and after reviewing yesterday's presentation and the recent news it is obvious that there is a lot going on behind the scenes that will reap dividends this year.
I was impressed that the company was able to license the Alzheimer's blood test developed at Georgetown University..
I do expect that the company will spin off the diagnostics division this year and I think that alone justifies the current share price.
p.s. Less than a penny downside and .15-.20 upside this year.